May 2, 2016

Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications

April 28, 2016

Sienna Biopharmaceuticals Announces $34 Million Series A Financing

April 19, 2016

Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA

April 19, 2016

Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting

April 4, 2016

Capricor Therapeutics Announces DSMB Recommends Continuation of HOPE-Duchenne Clinical Trial

March 21, 2016

Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II

March 17, 2016

Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma

March 17, 2016

Capricor Awarded $3.4 Million Grant from California Institute for Regenerative Medicine

March 16, 2016

Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research (AACR)

March 15, 2016

Capricor Therapeutics Announces $4 Million Registered Direct Offering

February 22, 2016

Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial

February 8, 2016

UroGen Pharma Strengthens Board of Directors and Senior Management Team

January 13, 2016

UroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset

January 13, 2016

Arno Therapeutics Completes $7.4 Million Common Stock Financing

January 13, 2016

Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers

January 7, 2016

Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies

January 5, 2016

Capricor Therapeutics to Present at Biotech Showcase 2016

December 21, 2015

Kite Pharma Appoints Industry Leader Shawn Cline Tomasello as Chief Commercial Officer

December 11, 2015

Kite Pharma Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 10, 2015

Capricor Therapeutics to Present at the 2015 JMP Securities DMD Forum

December 8, 2015

Kite Pharma Announces Proposed Public Offering of Common Stock

December 7, 2015

Kite Pharma Announces Clinical Biomarker Results of Anti-CD19 CAR T Cell Therapy at the 57th American Society of Hematology Annual Meeting (ASH)

December 7, 2015

Kite Pharma Presents Phase 1 Results From ZUMA-1 at the 57th American Society of Hematology (ASH) Annual Meeting

December 7, 2015

Kite Pharma Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Children and Young Adults

December 7, 2015

Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)